SCYNEXIS (NASDAQ:SCYX) and SUMMIT THERAPEU/S (NASDAQ:SMMT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, profitability, risk and valuation.

Risk & Volatility

SCYNEXIS has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, SUMMIT THERAPEU/S has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.


This table compares SCYNEXIS and SUMMIT THERAPEU/S’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SCYNEXIS -11,653.81% -230.55% -78.70%
SUMMIT THERAPEU/S -2,107.69% -59.95% -42.26%

Insider and Institutional Ownership

32.0% of SCYNEXIS shares are held by institutional investors. Comparatively, 8.3% of SUMMIT THERAPEU/S shares are held by institutional investors. 5.6% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for SCYNEXIS and SUMMIT THERAPEU/S, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SCYNEXIS 0 0 6 0 3.00
SUMMIT THERAPEU/S 0 1 1 0 2.50

SCYNEXIS presently has a consensus target price of $4.63, indicating a potential upside of 392.02%. SUMMIT THERAPEU/S has a consensus target price of $2.00, indicating a potential upside of 35.14%. Given SCYNEXIS’s stronger consensus rating and higher possible upside, research analysts clearly believe SCYNEXIS is more favorable than SUMMIT THERAPEU/S.

Valuation and Earnings

This table compares SCYNEXIS and SUMMIT THERAPEU/S’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SCYNEXIS $260,000.00 211.03 -$12.47 million ($0.49) -1.92
SUMMIT THERAPEU/S $56.50 million 0.84 $9.99 million $0.84 1.76

SUMMIT THERAPEU/S has higher revenue and earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than SUMMIT THERAPEU/S, indicating that it is currently the more affordable of the two stocks.


SCYNEXIS beats SUMMIT THERAPEU/S on 8 of the 14 factors compared between the two stocks.

SCYNEXIS Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.


Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with's FREE daily email newsletter.